IQVIA (NYSE:IQV) Hits New 52-Week Low - Here's What Happened

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as $146.06 and last traded at $147.20, with a volume of 197303 shares. The stock had previously closed at $154.73.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Mizuho cut their price objective on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research report on Wednesday. Truist Financial dropped their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday. Morgan Stanley lifted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Finally, UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Price Performance

The business's fifty day moving average price is $182.32 and its 200 day moving average price is $199.64. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market cap of $25.64 billion, a P/E ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Smith Group Asset Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth $1,616,000. Nordea Investment Management AB increased its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the fourth quarter worth about $941,000. Fifth Third Bancorp lifted its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after acquiring an additional 1,521 shares during the period. Finally, Graphene Investments SAS increased its position in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after purchasing an additional 2,700 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.